Published in AIDS Weekly, October 26th, 2009
"In the ACTG A5142 study, efavirenz showed greater virological efficacy than the boosted protease...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.